Anthropic IPO Marketing Expected to Start in Mid-October 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
 - EconoTimes)
Add as a preferred source on Google
RANCHO CORDOVA, Calif., Feb. 28, 2018 -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL) a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Phil Coelho, chief technology officer of ThermoGenesis Corp., Cesca’s device division, will be presenting at the 8th Spring Meeting of the International Society for BioProcess Technology (ISBiotech). ISBiotech is being held March 5-7, 2018 at the Hilton Norfolk The Main Hotel in Norfolk, Virginia.
Mr. Coelho’s presentation, “Automated, Closed System Manufacturing of CAR-T Cells,” is scheduled to take place on Wednesday, March 7 from 1:30-2:15pm EST.
For more information about the ISBiotech Spring Meeting, go to: www.isbiotech.org
About Cesca Therapeutics Inc.
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress platform that addresses the critical unmet need for better cellular manufacturing and controls (CMC) for the emerging CAR-T immunotherapy market. Cesca is an affiliated company of China-based Boyalife Group.
Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
[email protected]
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
[email protected]
